Financial Performance - Total revenue for Q3 2025 was $7.4 million, a 21% increase from $6.1 million in Q3 2024[5] - Total revenue for Q3 2025 was $7,367,000, a 21.3% increase from $6,073,000 in Q3 2024[20] - Product revenue increased to $6,934,000 in Q3 2025 from $6,021,000 in Q3 2024, representing a 15.2% growth[20] - Net loss for Q3 2025 was $8,503,000, compared to a net loss of $44,246,000 in Q3 2024, indicating a significant reduction in losses[20] Revenue Guidance - Full year 2025 revenue guidance is reiterated in the range of $26.0 to $30.0 million[7] - Q4 2025 revenue is expected to be between $7.5 and $7.9 million[7] Cost Management - Operating expenses were reduced by 66% to $11.9 million, with non-GAAP operating expenses down 40% to $9.7 million[5] - Research and development expenses for Q3 2025 were $2,844,000, down from $4,717,000 in Q3 2024, reflecting a 39.7% decrease[20] - Selling, general and administrative expenses were $9,064,000 in Q3 2025, slightly lower than $9,464,000 in Q3 2024[20] Profitability Metrics - Gross margin improved to 46%, up from (139)% in Q3 2024, with non-GAAP gross margin also at 46% compared to 26% in the prior year[5] - GAAP gross margin for Q3 2025 improved to 46% from a negative 139% in Q3 2024[22] - Non-GAAP gross profit for Q3 2025 was $3,401,000, compared to $1,597,000 in Q3 2024, showing a substantial improvement[22] Cash and Assets - The company ended Q3 2025 with cash and equivalents totaling $31.8 million[5] - Total current assets increased to $48,800,000 as of September 30, 2025, up from $39,489,000 as of December 31, 2024[18] - Total stockholders' equity increased to $49,799,000 as of September 30, 2025, up from $35,375,000 as of December 31, 2024[18] Product and Installation Metrics - Consumables and software revenues increased by 15% compared to the prior year[5] - The company sold 8,390 nanochannel array flowcells in Q3 2025, a 7% increase from 7,835 in Q3 2024[5] - Installed base of OGM systems reached 384, representing a 4% increase from 368 systems at the end of Q3 2024[5] - New OGM system installations are anticipated to exceed 25 for the full year 2025, up from previous expectations of 20 to 25[7] Liabilities - Total liabilities decreased to $29,263,000 as of September 30, 2025, down from $41,295,000 as of December 31, 2024[18]

Revenue Performance - Record annual revenue of $28.37 billion, up 4% year over year[4] - Quarterly revenue of $6.80 billion, down 3% year over year[4] - Display segment revenue for FY2025 at $1.06 billion, up from $885 million in FY2024[7] - Revenue from China accounted for 29% of total revenue in Q4 FY2025, slightly down from 30% in Q4 FY2024[17] Earnings and Profitability - Record annual GAAP EPS of $8.66, up 1% year over year, and record non-GAAP EPS of $9.42, up 9% year over year[4] - The company reported a diluted earnings per share of $2.38 for Q4 FY2025, compared to $2.09 in Q4 FY2024, reflecting a growth of 13.88%[13] - Non-GAAP earnings per diluted share for the three months ended October 26, 2025, was $2.17, compared to $2.32 in the prior year, a decrease of 6.5%[24] - GAAP reported net income for the three months ended October 26, 2025, was $1,897 million, an increase of 9.6% from $1,731 million in the same period last year[19] - Net income for FY2025 was $6,998 million, a decrease of 2.49% from $7,177 million in FY2024[13] Margins - Operating margin for Q4 FY2025 at 25.2%, down from 29.0% in Q4 FY2024[5] - Non-GAAP operating margin for FY2025 at 30.2%, up from 29.2% in FY2024[5] - Non-GAAP operating margin for Semiconductor Systems was 32.3% for the three months ended October 26, 2025, compared to 35.4% in the prior year[26] - Non-GAAP gross margin improved to 48.1% for the three months ended October 26, 2025, compared to 47.5% in the prior year[19] Expenses and Investments - Research, development, and engineering expenses increased to $917 million in Q4 FY2025 from $858 million in Q4 FY2024, representing a 6.87% increase[13] - Capital expenditures for FY2025 were $2,260 million, significantly higher than $1,190 million in FY2024, indicating increased investment in growth[16] - Restructuring charges of $181 million were recorded for the three months ended October 26, 2025, related to a workforce reduction plan[20] Cash Flow and Assets - Cash provided by operating activities for FY2025 was $7,958 million, down from $8,677 million in FY2024[16] - Cash provided by operating activities for the three months ended October 26, 2025, was $2,828 million, compared to $2,575 million in the same period last year, an increase of 9.8%[31] - Non-GAAP free cash flow for the twelve months ended October 26, 2025, was $5,698 million, down from $7,487 million in 2024, a decrease of 23.9%[31] - Total assets increased to $36,299 million in FY2025 from $34,409 million in FY2024, marking a growth of 5.49%[15] - Total stockholders' equity rose to $20,415 million in FY2025, compared to $19,001 million in FY2024, an increase of 7.43%[15] Future Outlook - Company is preparing for higher demand starting in the second half of calendar 2026, focusing on R&D for faster and more energy-efficient technologies[3] Tax and Valuation - The company recognized a $403 million valuation allowance against deferred tax assets related to corporate alternative minimum tax credits in the third quarter of fiscal 2025[22]

Financial Performance - Revenue for Q3 2025 was $0.1 million, a decrease of 83.4% compared to $0.6 million in Q3 2024, primarily due to a reduction in grant revenue[7] - Operating expenses were approximately $7.1 million, a decrease of 32.6% year-over-year from $10.6 million in Q3 2024[7] - Net loss for Q3 2025 was $5.9 million, or $0.16 per fully diluted share, compared to a net loss of $9.7 million, or $0.32 per fully diluted share in Q3 2024[7] - The operating loss for Q3 2025 was $7.0 million, a decrease from $10.2 million in Q3 2024[7] - For the three months ended September 30, 2025, the net loss was $5,886,823, an improvement from a net loss of $9,696,455 in the same period of 2024, representing a reduction of approximately 39%[18] - Adjusted EBITDA for Q3 2025 was $(6,301,839), compared to $(8,825,436) in Q3 2024, indicating a year-over-year improvement of about 29%[18] - Stock-based compensation expense decreased to $500,585 in Q3 2025 from $1,045,583 in Q3 2024, reflecting a reduction of approximately 52%[18] - Interest income, net, decreased to $(13,194) in Q3 2025 from $(263,335) in Q3 2024, indicating a decline of about 95%[18] - Depreciation and amortization expenses were $267,383 in Q3 2025, down from $351,235 in Q3 2024, representing a decrease of approximately 24%[18] - The realized gain on investments was $(41,542) in Q3 2025, compared to $(293,067) in Q3 2024, indicating a reduction of about 86%[18] - The income tax provision showed a benefit of $(1,166,593) in Q3 2025, contrasting with a provision of $22,189 in Q3 2024, marking a significant change[18] - Gain on disposition of assets was $(4,000) in Q3 2025, slightly higher than $(3,513) in Q3 2024[18] Cash and Funding - Cash, cash equivalents, and marketable securities totaled $11.4 million as of September 30, 2025, up from $2.9 million at the end of 2024[7] - The company closed a Registered Direct Offering (RDO) with gross proceeds of approximately $3.8 million before expenses, and subsequently closed another RDO with gross proceeds of approximately $7.0 million[7] Strategic Initiatives - Co-Diagnostics launched a dedicated AI business unit to integrate existing and planned AI applications into the Co-Dx Primer Ai platform[5] - The company signed a definitive agreement with Arabian Eagle Manufacturing to develop and commercialize Co-Dx technologies in Saudi Arabia and 18 additional MENA markets[7] - The company is pursuing a strategic transaction with Maxim Group, which may include a SPAC transaction for its India joint venture, CoSara[5] - The company developed a proprietary sample preparation instrument to streamline workflow for point-of-care Co-Dx PCR Mycobacterium Tuberculosis Test[7] Operational Efficiency - The company continues to focus on improving operational efficiency and reducing losses as indicated by the overall financial metrics[18]

Financial Performance - Worldwide net sales for Q3 2025 totaled $270.2 million, a decrease of 6.1% from $287.8 million in Q3 2024[5]. - Operating loss for Q3 2025 was $22 million, with an operating margin of (8.0)%, compared to an operating loss of $24.5 million and an operating margin of (8.5)% in Q3 2024[2][8]. - Gross profit for Q3 2025 was $132.4 million, down 6.9% from $142.2 million in Q3 2024, resulting in a gross margin of 49.0%[5][19]. - Adjusted net loss for Q3 2025 was $32.8 million, with an adjusted net loss per diluted share of $0.63, compared to an adjusted net loss of $30.0 million and $0.56 per diluted share in Q3 2024[8]. - The company expects worldwide net sales to decline in the mid-teens for the full year 2025[15]. - Adjusted EBITDA for the fiscal year 2025 totaled $24.2 million, compared to a loss of $39.6 million in fiscal year 2024[24][25]. - For the 13 weeks ended October 4, 2025, the net income attributable to Fossil Group, Inc. was $(39.9) million, resulting in a diluted loss per share of $(0.76)[26]. - For the 40 weeks ended October 4, 2025, the net income attributable to Fossil Group, Inc. was $(59.7) million, with a diluted loss per share of $(1.13)[27]. Sales and Market Performance - Direct to consumer sales decreased by 27% in Q3 2025, with comparable retail sales declining by 22%[5]. - Americas segment net sales decreased from $121.3 million to $109.7 million, a decline of approximately 9.8%[22]. - The company reported a net sales increase in the Asia segment from $69.0 million to $70.2 million, an increase of approximately 1.7%[22]. - Total net sales for the 13 weeks ended October 4, 2025, were $270.2 million, down 6.1% from $287.8 million in the same period the previous year[22]. Financial Position and Liquidity - Total liquidity as of October 4, 2025, was $101.9 million, including $79.2 million in cash and cash equivalents[7]. - Total assets decreased from $812.4 million in September 2024 to $701.0 million in October 2025, a decline of approximately 13.7%[20]. - Total current assets fell from $575.9 million to $471.1 million, representing a decrease of about 18.2%[20]. - Long-term debt slightly decreased from $173.4 million in September 2024 to $169.1 million in October 2025, a reduction of about 1.8%[20]. - Stockholders' equity dropped significantly from $161.9 million to $96.1 million, a decrease of approximately 40.5%[20]. - Total liabilities decreased from $650.5 million to $604.9 million, reflecting a decline of about 7.0%[20]. Restructuring and Operational Changes - The company has completed a balance sheet transformation, significantly strengthening its financial position[2][4]. - The company experienced a restructuring expense of $58.1 million in fiscal year 2025, compared to $47.1 million in fiscal year 2024[24]. - The total store count decreased from 251 stores on September 28, 2024, to 204 stores on October 4, 2025, with significant closures in the Americas and Europe[28]. Other Financial Metrics - The company reported an interest expense of $(13.0) million for the 40 weeks ended October 4, 2025[27]. - The provision for income taxes for the 40 weeks was $17.6 million, indicating a tax burden despite the net loss[27]. - The operating income for the same period was $(21.7) million, with an operating margin of (8.0)% of net sales[26]. - The operating income for the 40 weeks was $(19.9) million, reflecting an operating margin of (2.7)% of net sales[27]. - The company experienced a loss before income taxes of $(42.4) million for the 40 weeks ended October 4, 2025[27]. - The company recorded a loss on extinguishment of debt of $(11.5) million for the 40 weeks ended October 4, 2025[27].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of I ...

Financial Performance - STARZ reported third quarter revenue of $320.9 million, a decrease from $346.9 million in the same quarter last year[4]. - The company experienced a net loss of $(52.6) million, translating to a net loss per share of $(3.15)[4]. - Adjusted OIBDA for the quarter was $21.8 million, with a total Adjusted OIBDA leverage ratio of 3.4x[4][6]. - For the six months ended September 30, 2025, the net loss from continuing operations was $95.1 million, compared to a net loss of $29.5 million for the same period in 2024[13]. - The company reported adjusted OIBDA of $83.5 million for the six months ended September 30, 2025, an increase from $24.7 million in the same period of 2024[15]. - The restructuring and other costs for the six months ended September 30, 2025, totaled $11.4 million, compared to a recovery of $1.7 million in the same period of 2024[18]. Subscriber Metrics - U.S. OTT subscriber growth reached 520,000 year-to-date and 670,000 year-over-year, totaling 12.3 million U.S. OTT subscribers[4]. - Total North American subscribers increased by 120,000 to 19.2 million, with Canadian subscribers rising by 250,000 due to the resolution of a carriage dispute[4]. - Total subscribers in the United States decreased to 17.46 million as of September 30, 2025, down from 18.00 million as of March 31, 2025, reflecting a decline of approximately 3%[22]. - The company reported a total of 12.29 million OTT subscribers in the United States as of September 30, 2025, a slight decrease from 12.30 million as of March 31, 2025[22]. Cash and Debt Management - STARZ ended the quarter with $300 million outstanding on its Term Loan A credit facility and total net debt of $588.1 million[4]. - STARZ's cash and cash equivalents increased to $37.0 million from $17.8 million in the previous quarter[10]. - The company had cash and cash equivalents of $37.0 million at the end of the period, an increase from $17.8 million at the beginning of the period[13]. - The company experienced a net cash provided by operating activities of $39.3 million for continuing operations, a significant improvement from a net cash used of $17.8 million in the prior year[13]. Capital Expenditures and Programming Costs - Capital expenditures for the six months ended September 30, 2025, were $12.1 million, compared to $9.6 million for the same period in 2024[13]. - Programming amortization for the six months ended September 30, 2025, was $319.3 million, slightly down from $331.1 million in the same period of 2024[13]. - The adjusted share-based compensation expense for the six months ended September 30, 2025, was $8.9 million, compared to $9.3 million in the same period of 2024[20]. Strategic Outlook - The company plans to generate new revenue through content licensing and improve ownership of series on the network[3]. - STARZ's programming mix includes a strong slate of originals aimed at women and underrepresented audiences, enhancing its market position[3][7]. - The company maintains its previously provided 2025 outlook, indicating confidence in future performance[1][3].

Financial Performance - Third Quarter revenue was $320.9 million, a decrease from $346.9 million in the same quarter last year[4] - Operating loss for the quarter was $(34.8) million, compared to $(17.0) million in the prior year[12] - The company reported a net loss of $(52.6) million for the quarter, with a net loss per share of $(3.15)[4][12] - For the six months ended September 30, 2025, the net loss from continuing operations was $95.1 million, compared to a net loss of $29.5 million for the same period in 2024[13] - The company reported adjusted OIBDA of $83.5 million for the six months ended September 30, 2025, compared to $24.7 million for the same period in 2024, reflecting a significant improvement[15] Subscriber Metrics - U.S. OTT subscriber growth reached 520,000 year-to-date and 670,000 year-over-year, totaling 12.3 million U.S. OTT subscribers[4] - Total North American subscribers increased by 120,000 to 19.2 million, driven by a 250,000 increase in Canadian subscribers[4] - As of September 30, 2025, total subscribers in the United States decreased to 17.46 million from 18.00 million as of March 31, 2025, indicating a decline in subscriber base[22] - The company reported a decrease in linear subscribers in the U.S. to 5.17 million as of September 30, 2025, down from 6.21 million as of September 30, 2024[22] Cash Flow and Debt - The company ended the quarter with total net debt of $588.1 million and an undrawn revolving credit facility of $150 million[4] - The company had cash and cash equivalents of $37.0 million at the end of the period, up from $17.8 million at the beginning of the period[13] - The net cash provided by operating activities for continuing operations was $39.3 million, a turnaround from a net cash used of $17.8 million in the prior year[13] Costs and Expenditures - Programming amortization for the six months ended September 30, 2025, was $319.3 million, slightly down from $331.1 million in the same period of 2024[13] - Total restructuring and other costs for the six months ended September 30, 2025, amounted to $11.4 million, compared to a recovery of $1.7 million in the same period of 2024[18] - The company’s capital expenditures for the six months ended September 30, 2025, were $12.1 million, compared to $9.6 million in the same period of 2024[13] - The adjusted share-based compensation expense for the six months ended September 30, 2025, was $8.9 million, compared to $9.3 million in the same period of 2024[20] Strategic Outlook - STARZ management reiterated its 2025 outlook, focusing on generating new revenue through content licensing[3] - STARZ aims to scale its core audience of women and underrepresented audiences with a strong slate of originals planned for the next year[3] Engagement Metrics - Engagement on the STARZ App reached a 12-month high during the period[1] Adjusted OIBDA - Adjusted OIBDA for the quarter was $21.8 million, with a trailing twelve-month total of $173.2 million[4][6]

Exhibit 99.1 Starz Entertainment Corp. Reports Results for the Third Quarter Ended September 30, 2025 Third Quarter Revenue was $320.9 Million Third Quarter Operating Loss was $(34.8) Million Third Quarter Adjusted OIBDA was $21.8 Million Total Revenue, OTT Revenue, and U.S. OTT Subscriber Growth U.S. OTT Subscriber Growth of 520,000 YTD and 670,000 YoY Engagement on STARZ App Reached 12-Month High During Period "STARZ reported a great quarter both operationally and financially, and we expect to continue ou ...

Financial Performance - Total current assets decreased to $6,517,248 as of September 30, 2025, down from $7,934,883 on December 31, 2024, representing a decline of approximately 18%[13] - Revenue from government contracts was $0 for the three months ended September 30, 2025, compared to $2,789,484 for the same period in 2024, indicating a decrease of 100%[15] - The net loss for the nine months ended September 30, 2025, was $17,046,348, compared to a net loss of $16,729,642 for the same period in 2024, reflecting an increase in loss of approximately 2%[19] - The company reported a basic and diluted net loss per common share of $0.31 for the three months ended September 30, 2025[15] - The net loss for the three-month period ended September 30, 2025, was $6,318,914, an increase of $503,446 compared to the net loss of $5,815,468 in the same period in 2024[65] Operating Expenses - Total operating expenses for the nine months ended September 30, 2025, were $19,686,436, slightly down from $19,890,039 in the same period of 2024, a decrease of about 1%[15] - Total operating expenses for the three-month period ended September 30, 2025, were $6,373,215, down from $8,644,060 in the same period in 2024, a decrease of $2,270,845[65] - General and administrative expenses increased by $88,535 (7.1%) for the three-month period and $774,787 (20.5%) for the nine-month period ended September 30, 2025, compared to the same periods in 2024[68] Cash Flow and Financing - Cash and cash equivalents at the end of the period were $5,008,997, down from $8,592,523 at the end of September 30, 2024, a decrease of about 42%[19] - Net cash used in operating activities for the nine months ended September 30, 2025, was $16,512,193, primarily due to a net loss of $17,046,348[70] - Net cash provided by financing activities was $16,041,861 for the nine-month period ended September 30, 2025, compared to $19,082,548 for the same period in 2024[72] - The company closed a registered direct offering of common stock and warrants in the first quarter of 2025, generating approximately $7.9 million in net proceeds[74] - The company raised $15,885,652 from the sale of common stock and warrants during the nine months ended September 30, 2025[19] - As of September 30, 2025, the company believes existing cash and cash equivalents are sufficient to fund operations into December 2025[76] - The company anticipates needing substantial additional funding to support ongoing operations and product development[78] - The sale of additional equity may result in dilution to stockholders, and the company may also consider debt financing, which could impose operational restrictions[79] Research and Development - GeoVax's lead clinical program, GEO-CM04S1, is currently in three Phase 2 clinical trials targeting COVID-19[22] - The company is developing a vaccine targeting Mpox and smallpox, with a Phase 3 immuno-bridging study expected to initiate in late 2026[22] - The company plans to initiate a Phase 3 trial for the GEO-MVA vaccine candidate in 2026, bypassing traditional Phase 1 and 2 studies[56] - The company received a development award from BARDA to support the advancement of GEO-CM04S1 into a Phase 2b study, which was later terminated[56] - The company is developing a continuous avian cell line manufacturing platform to enhance the production of its Modified Vaccinia Ankara (MVA)-based vaccines[56] - The company expects research and development expenditures to increase as it advances existing and future product candidates through clinical trials[58] - Research and development expenses decreased by $2,359,380 (31.9%) for the three-month period and by $978,390 (6.1%) for the nine-month period ended September 30, 2025, compared to the same periods in 2024[67] - Research and development expenses for the three-month and nine-month periods of 2025 included stock-based compensation of $130,323 and $390,962, respectively[67] Stockholder Equity - Stockholders' equity decreased to $4,907,078 as of September 30, 2025, from $5,048,535 on December 31, 2024, a decline of approximately 3%[13] - The company has 40,027,849 outstanding warrants as of September 30, 2025, with a weighted average exercise price of $0.70[41] - The company expects to recognize $1,619,481 of unrecognized stock-based compensation expense over a weighted-average period of 2.1 years as of September 30, 2025[44] - Stock-based compensation expense for the nine-month period ended September 30, 2025, was $863,030, an increase of approximately 157.5% compared to $335,132 for the same period in 2024[44] Other Financial Metrics - Total prepaid expenses decreased from $1,768,533 on December 31, 2024, to $1,508,251 on September 30, 2025, a reduction of approximately 14.7%[28] - Total accrued expenses decreased from $1,257,572 on December 31, 2024, to $847,766 on September 30, 2025, a reduction of approximately 32.5%[28] - Interest income for the three-month and nine-month periods ended September 30, 2025, was $54,301 and $150,943, respectively, compared to $53,191 and $91,611 for the same periods in 2024[69] - The company remains in a cumulative loss position with no provision for income taxes recorded as of September 30, 2025[49] - The company has not generated any revenue from product sales to date, relying solely on government grants and contracts[55] - The company has not generated any product revenue to date and does not expect to do so until regulatory approval is obtained[73]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-39158 AppTech Payments Corp. (Exact Name of Registrant as Specified in it ...